Wednesday, July 8, 2026

Patent intelligence · US

US 11351276

Radiopharmaceutical compositions of radioactive halogenated benzylguanidine

granted A61KA61K47/10A61K47/12A61K47/22
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 16
Applicant portfolio 138
Patent details — US 11351276
Jurisdiction
US
Status
granted
Grant date
Jun 7, 2022
Expiration
Jun 2, 2042
Claims
16
CPC classes
A61K, A61K47/10, A61K47/12, A61K47/22
View on Google Patents ↗

Quick answer

US 11351276 (Radiopharmaceutical compositions of radioactive halogenated benzylguanidine) is held by Jubilant Draximage Inc.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K47/10, A61K47/12, A61K47/22, A61K51/04, A61K51/0406

More from Jubilant Draximage Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12391732

    Articles comprising a silk polypeptide for antigen delivery

    Ludwig-Maximilians-Universitat Munchen · Expires Aug 14, 2045

    granted
  2. US 12379385

    Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function

    Maximus Diagnostic Technologies LLC · Expires Jul 31, 2045

    granted
  3. US 12318397

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Expires May 29, 2045

    granted
  4. US 12290524

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Expires May 1, 2045

    granted
  5. US 12171837

    Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates

    Ludwig-Maximilians-Universitat Munchen · Expires Dec 19, 2044

    granted
  6. US 12168718

    Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel

    Julius-Maximilians-Universitat Wurzburg · Expires Dec 12, 2044

    granted
  7. US 12144876

    Security mechanisms for radiopharmaceutical elution system and elution process

    Jubilant Draximage Inc. · Expires Nov 14, 2044

    granted
  8. US 12133890

    Antigen-binding polypeptide targeting B7H3 and application thereof

    NINGBO T-MAXIMUM BIOPHARMACEUTICALS CO., LTD. · Expires Oct 31, 2044

    granted

Frequently asked questions

What is US patent 11351276?

US 11351276 (Radiopharmaceutical compositions of radioactive halogenated benzylguanidine) is held by Jubilant Draximage Inc.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11351276?

Jubilant Draximage Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.

When does US 11351276 expire?

Our index shows an expiration date of Jun 2, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.